Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Applied DNA Sciences Inc - SIC # 2835 - IN VITRO AND IN VIVO DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
APDN
Nasdaq
2835
https://adnas.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Applied DNA Sciences Inc
Applied DNA Announces 1-For-20 Reverse Stock Split
- Apr 22nd, 2024 8:05 pm
Applied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea(TM) RNAP, Progresses Towards GMP Linea(TM) IVT Production Start
- Mar 18th, 2024 1:00 pm
Applied DNA to Showcase Linea(TM) DNA and Linea(TM) IVT Platforms at 24th Annual World Vaccine Congress
- Mar 14th, 2024 2:00 pm
Is Applied DNA Sciences (APDN) Outperforming Other Industrial Products Stocks This Year?
- Feb 21st, 2024 2:40 pm
Applied DNA Sciences First Quarter 2024 Earnings: Beats Expectations
- Feb 10th, 2024 2:31 pm
Applied DNA Sciences, Inc. (NASDAQ:APDN) Q1 2024 Earnings Call Transcript
- Feb 10th, 2024 1:48 pm
Q1 2024 Applied DNA Sciences Inc Earnings Call
- Feb 9th, 2024 11:17 am
Applied DNA Sciences (APDN) Reports Q1 Loss, Tops Revenue Estimates
- Feb 8th, 2024 10:40 pm
Applied DNA Announces First Quarter Fiscal Year 2024 Financial Results
- Feb 8th, 2024 9:05 pm
Applied DNA to Report First Quarter Fiscal 2024 Financial Results on Thursday, February 8, 2024
- Feb 5th, 2024 6:00 pm
Applied DNA Announces Closing of $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Feb 2nd, 2024 9:15 pm
Applied DNA Announces $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Jan 31st, 2024 1:00 pm
Applied DNA Announces Joint Development Agreement to Integrate Linea(TM) IVT Platform into CDMO Kudo Biotechnology’s mRNA Manufacturing Workflow
- Dec 14th, 2023 1:00 pm
Applied DNA Sciences, Inc. (NASDAQ:APDN) Q4 2023 Earnings Call Transcript
- Dec 12th, 2023 1:10 pm
Applied DNA Announces Fourth Quarter Fiscal Year 2023 Financial Results
- Dec 7th, 2023 9:05 pm
Applied DNA to Report Fiscal 2023 Fourth Quarter and Year End Financial Results on December 7, 2023
- Dec 5th, 2023 1:30 pm
Applied DNA Announces Receipt of Linea(TM) DNA Follow-On Order for Cancer Diagnostic Application
- Nov 28th, 2023 1:30 pm
Applied DNA Extends Application of Linea(TM) IVT Platform to saRNA (self-amplifying mRNA)
- Nov 16th, 2023 1:30 pm
Applied DNA Ships First saRNA (self-amplifying mRNA) IVT Template Generated by Linea(TM) DNA Platform
- Nov 9th, 2023 2:15 pm
Applied DNA Partners with Cornell University College of Veterinary Medicine to Accelerate Development of Veterinary Vaccine Platform Targeting Diseases that Impact High-Value Animals
- Sep 14th, 2023 1:00 pm
Scroll